atopic dermatitis

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.

Arcutis reports Q1 2026 ZORYVE revenue of $105.4 million, up 65% year-over-year, with expanded pediatric development and reaffirmed full-year guidance of $480-495 million.

Arcutis reports Q1 2026 results May 6 as company presents new Phase 2 pediatric atopic dermatitis data at dermatology conference.

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Arcutis director sells 10,000 shares via pre-planned trading arrangement as stock surges 65%. ZORYVE revenue hit $372.1M in 2025, up 123% YoY, with company achieving positive operating cash flow.

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.

Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.

Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.